76218 Federal Register / Vol. 88, No. 213 / Monday, November 6, 2023 / Notices 

catalogs or other public documents 

during the normal course of business. 

The nominal amount of burden imposed 

on the public is simply to relay the 

requested information. 

Respondents: 14,000. 

Responses per Respondent: 1. 

Total Annual Responses: 14,000. 

Hours per Response: 0.03 (2 minutes). 

Total Burden Hours: 420. 

C. Public Comments 

Public comments are particularly 

invited on: Whether this collection of 

information is necessary and whether it 

will have practical utility; whether our 

estimate of the public burden of this 

collection of information is accurate and 

based on valid assumptions and 

methodology; and ways to enhance the 

quality, utility, and clarity of the 

information to be collected. 

Obtaining Copies of Proposals: 

Requesters may obtain a copy of the 

information collection documents from 

the Regulatory Secretariat Division, at 

GSARegSec@gsa.gov. 

Please cite OMB Control No. 3090– 

0250, FSS Contract Administration 

Information, in all correspondence. 

Jeffrey A. Koses, 

Senior Procurement Executive, Office of 

Acquisition Policy, Office of Governmentwide Policy. 

[FR Doc. 2023–24433 Filed 11–3–23; 8:45 am] 

BILLING CODE 6820–14–P 

GENERAL SERVICES 

ADMINISTRATION 

[Notice-MRB–2023–06; Docket No. 2023– 

0002; Sequence No. 37] 

GSA Acquisition Policy Federal 

Advisory Committee; Notification of 

Upcoming Web-Based Public Meeting 

AGENCY: Office of Government-wide 

Policy (OGP), General Services 

Administration (GSA). 

ACTION: Meeting notice. 

SUMMARY: GSA is providing notice of a 

meeting of the GSA Acquisition Policy 

Federal Advisory Committee 

(hereinafter ‘‘the Committee’’ or ‘‘the 

GAP FAC’’) in accordance with the 

requirements of the Federal Advisory 

Committee Act (FACA). This meeting 

will be open to the public, accessible via 

webcast. Information on attending and 

providing written public comment is 

under the SUPPLEMENTARY INFORMATION

section. 

DATES: The GAP FAC will hold an open 

public meeting on Tuesday, December 

5, 2023, from 1 p.m. to 4:30 p.m. eastern 

standard time (EST). 

ADDRESSES: The meeting will be 

accessible via webcast. Registrants will 

receive the webcast information before 

the meeting. 

FOR FURTHER INFORMATION CONTACT: 

Boris Arratia, Designated Federal 

Officer, OGP, 703–795–0816, or email: 

boris.arratia@gsa.gov; or Stephanie 

Hardison, OGP, 202–258–6823, or 

email: stephanie.hardison@gsa.gov. 

Additional information about the 

Committee, including meeting materials 

and agendas, are available on-line at 

https://gsa.gov/policy-regulations/ 

policy/acquisition-policy/gsaacquisition-policy-federal-advisorycommittee. 

SUPPLEMENTARY INFORMATION: 

Purpose of the Meeting 

The purpose of this meeting is for 

each of the three subcommittees (Policy 

and Practice, Industry Partnerships, and 

Acquisition Workforce) to present 

recommendations to the full Committee. 

The Committee will, in turn, deliberate 

and vote on GAP FAC recommendations 

to be delivered to the GSA 

Administrator. 

Meeting Agenda 

• Opening Remarks 

• Guest Speaker 

• Acquisition Workforce Subcommittee 

Recommendations and Discussion 

• Vote on recommendations 

• Industry Partnerships Subcommittee 

Recommendations and Discussion 

• Vote on recommendations 

• Policy and Practices Subcommittee 

Recommendations and Discussion 

• Vote on recommendations 

• Closing Remarks and Adjourn 

Meeting Registration 

This meeting is open to the public 

and will be accessible by webcast. 

Registration information is located on 

the GAP FAC website: https://

www.gsa.gov/policy-regulations/policy/ 

acquisition-policy/gsa-acquisitionpolicy-federal-advisory-committee. 

Public attendees who want to attend 

virtually will need to register no later 

than 5 p.m. EST, on Monday, December 

4, 2023 to obtain the meeting webcast 

information. All registrants will be 

asked to provide their name, affiliation, 

and email address. After registration, 

individuals will receive webcast access 

information details via email. 

Public Comments: 

Written public comments are being 

accepted via email at gapfac@gsa.gov. 

To submit a written public comment, 

please email at gapfac.gsa.gov and 

include your name, organization name 

(if applicable). 

Jeffrey A. Koses, 

Senior Procurement Executive, Office of 

Acquisition Policy, Office of Governmentwide Policy. 

[FR Doc. 2023–24432 Filed 11–3–23; 8:45 am] 

BILLING CODE 6820–RV–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2023–P–2536] 

Determination That FORADIL 

(Formoterol Fumarate) Inhalation 

Powder, 0.012 Milligrams, Was Not 

Withdrawn From Sale for Reasons of 

Safety or Effectiveness 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA, the Agency, or 

we) has determined that FORADIL 

(formoterol fumarate) inhalation 

powder, 0.012 milligrams (mg)/ 

inhalation (inh), was not withdrawn 

from sale for reasons of safety or 

effectiveness. This determination will 

allow FDA to approve abbreviated new 

drug applications (ANDAs) for 

formoterol fumarate inhalation powder, 

0.012 mg/inh, if all other legal and 

regulatory requirements are met. 

FOR FURTHER INFORMATION CONTACT: Joe 

Thomas, Center for Drug Evaluation and 

Research, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 51, Rm. 6217, Silver Spring, 

MD 20993–0002, 202–815–5571, 

joseph.thomas1@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Section 

505(j) of the Federal Food, Drug, and 

Cosmetic Act (FD&C Act) (21 U.S.C. 

355(j)) allows the submission of an 

ANDA to market a generic version of a 

previously approved drug product. To 

obtain approval, the ANDA applicant 

must show, among other things, that the 

generic drug product: (1) has the same 

active ingredient(s), dosage form, route 

of administration, strength, conditions 

of use, and (with certain exceptions) 

labeling as the listed drug, which is a 

version of the drug that was previously 

approved; and (2) is bioequivalent to the 

listed drug. ANDA applicants do not 

have to repeat the extensive clinical 

testing otherwise necessary to gain 

approval of a new drug application 

(NDA). 

Section 505(j)(7) of the FD&C Act 

requires FDA to publish a list of all 


ddrumheller on DSK120RN23PROD with NOTICES1